PURPOSE: Our purpose was to assess the effect of pretreatment with oral contraceptives (OCs) on the formation of functional ovarian cysts during pituitary suppression with gonadotropin-releasing hormone (GnRH) agonists, subsequent follicular development, and pregnancy rates. METHODS: A retrospective case-controlled study of 31 in vitro fertilization (IVF) patients, all of whom in a previous cycle had commenced the long protocol of GnRH-agonist (Buserelin) in the early follicular phase and were pretreated in a subsequent cycle with 2 weeks of an OC containing 30 micrograms of ethinyl estradiol and 150 micrograms of desogestrel prior to GnRH-agonist administration, was undertaken. Follow-up visits were arranged after a minimum of 11 days of GnRH-agonist administration and weekly thereafter until pituitary suppression was achieved. RESULTS: Cysts were detected in 16 (51.6%) of the 31 patients not pretreated with OCs, and in 0 (0%) of the 31 patients pretreated with OCs (odds ratio = 67.1; 95% confidence interval = 5.6-350.7). Patients pretreated with OCs achieved pituitary suppression more rapidly (median difference = 4 days; 95% confidence interval = 2-7) and had comparable gonadotropin requirements and pregnancy rates. CONCLUSIONS: Pretreatment with OCs prior to pituitary suppression in the early follicular phase decreases ovarian cyst formation, without an apparent effect on subsequent follicular recruitment or pregnancy rates.
PURPOSE: Our purpose was to assess the effect of pretreatment with oral contraceptives (OCs) on the formation of functional ovarian cysts during pituitary suppression with gonadotropin-releasing hormone (GnRH) agonists, subsequent follicular development, and pregnancy rates. METHODS: A retrospective case-controlled study of 31 in vitro fertilization (IVF) patients, all of whom in a previous cycle had commenced the long protocol of GnRH-agonist (Buserelin) in the early follicular phase and were pretreated in a subsequent cycle with 2 weeks of an OC containing 30 micrograms of ethinyl estradiol and 150 micrograms of desogestrel prior to GnRH-agonist administration, was undertaken. Follow-up visits were arranged after a minimum of 11 days of GnRH-agonist administration and weekly thereafter until pituitary suppression was achieved. RESULTS: Cysts were detected in 16 (51.6%) of the 31 patients not pretreated with OCs, and in 0 (0%) of the 31 patients pretreated with OCs (odds ratio = 67.1; 95% confidence interval = 5.6-350.7). Patients pretreated with OCs achieved pituitary suppression more rapidly (median difference = 4 days; 95% confidence interval = 2-7) and had comparable gonadotropin requirements and pregnancy rates. CONCLUSIONS: Pretreatment with OCs prior to pituitary suppression in the early follicular phase decreases ovarian cyst formation, without an apparent effect on subsequent follicular recruitment or pregnancy rates.
Entities:
Keywords:
Americas; Biology; Canada; Case Control Studies; Contraception; Contraceptive Methods; Demographic Factors; Developed Countries; Diseases; Endocrine System; Family Planning; Fertility; Fertility Measurements; Gonadotropins; Gonadotropins, Pituitary; Hormones; North America; Northern America; Oral Contraceptives; Ovarian Cysts; Physiology; Population; Population Dynamics; Pregnancy Rate; Research Methodology; Research Report; Retrospective Studies; Studies
Authors: J Cohen; C Debache; P Solal; A M Serkine; B Achard; A Boujenah; J P Pez; X Paris; J Robert; V Loffredo Journal: Hum Reprod Date: 1987-01 Impact factor: 6.918
Authors: J Adams; S Franks; D W Polson; H D Mason; N Abdulwahid; M Tucker; D V Morris; J Price; H S Jacobs Journal: Lancet Date: 1985 Dec 21-28 Impact factor: 79.321
Authors: Krzysztof Lukaszuk; Joanna Liss; Michal Kunicki; Waldemar Kuczynski; Ewa Pastuszek; Grzegorz Jakiel; Lukasz Plociennik; Krzysztof Zielinski; Judyta Zabielska Journal: Biomed Res Int Date: 2015-04-02 Impact factor: 3.411